Skip to Main Content

In a surprise ruling, a federal judge on Thursday sided with Amgen in a patent dispute — effectively banning Sanofi and Regeneron Pharmaceuticals from selling a competing cholesterol drug.

In 30 days, Sanofi and Regeneron will no longer be able to sell their treatment, Praluent, in the US, leaving Amgen’s Repatha as the sole drug of its type on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!